Adverum Sets Board Slate for 2021 AM, Reiterates Commitment to Stockholder Value Creation

 Responds to Intent to Nominate Directors from Sonic Fund

Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that its Board of Directors is expected to nominate a Board slate consisting of three independent directors – Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. – for reelection at the 2021 Annual Meeting of Stockholders as Class I directors with terms expiring in 2024. Following the 2021 Annual Meeting, Adverum will have a continuing Board of nine directors who bring extensive biotechnology healthcare expertise across R&D, clinical development and regulatory affairs, and commercialization, as well as deep leadership, operational and financial acumen. The date of the Annual Meeting will be shared in the 2021 proxy statement.

https://www.biospace.com/article/releases/adverum-announces-board-slate-for-2021-annual-meeting-and-reiterates-commitment-to-stockholder-value-creation/